2013-04-30 15:22:32 UTC

Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis

May 2, 2013

Yujin Hoshida and colleagues report in Gastroenterology that a 186-gene signature used to predict outcomes of patients with hepatocellular carcinoma (HCC) is also associated with outcomes of patients with hepatitis C–related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent the development of HCC.

Cirrhosis affects 1 to 2 percent of the world population and is the major risk factor for hepatocellular carcinoma (HCC). Hepatitis C cirrhosis–related HCC is the most rapidly increasing cause of cancer death in the U.S. Non-invasive methods have been developed to identify patients with asymptomatic early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. Yujin Hoshida and colleagues investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients with newly diagnosed cirrhosis but without HCC. Publishing in Gastroenterology, they report that a 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C–related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent the development of HCC. 

Gastroenterology 2013: 144(5), 1024-1030

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.